Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Asset Resilience Ratio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd asset resilience ratio. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has an Asset Resilience Ratio of 11.06% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2022)
Asset resilience ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2022. This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceut for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688505 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥280.00 Million | 11.06% |
| Total Liquid Assets | CN¥280.00 Million | 11.06% |
Asset Resilience Insights
- Moderate Liquidity: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has 11.06% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2005–2022)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd asset resilience ratio by year from 2005 to 2022. The table below shows the annual Asset Resilience Ratio data for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.12% | CN¥33.32 Million ≈ $4.88 Million |
CN¥2.98 Billion ≈ $435.48 Million |
+1.12pp |
| 2011-12-31 | 0.00% | CN¥11.00K ≈ $1.61K |
CN¥358.88 Million ≈ $52.52 Million |
-0.04pp |
| 2010-12-31 | 0.05% | CN¥143.00K ≈ $20.93K |
CN¥304.15 Million ≈ $44.51 Million |
+0.02pp |
| 2006-12-31 | 0.03% | CN¥38.00K ≈ $5.56K |
CN¥145.02 Million ≈ $21.22 Million |
-0.31pp |
| 2005-12-31 | 0.33% | CN¥475.00K ≈ $69.51K |
CN¥142.91 Million ≈ $20.91 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more